LifeStance Health Group, Inc.

Valuation Analysis

About the Company

LifeStance Health Group, Inc. en bref

LifeStance Health Group, Inc. (LFST) is currently trading at 7,83 € with a market capitalization of 3,0 Md €. The trailing P/E ratio stands at 149.67x, with a forward P/E of 22.91x. The 52-week range spans from 3,26 € to 7,94 €; the current price is 1.4% below the yearly high. Year-over-year revenue growth stands at +21.2%. The net profit margin stands at 1.55%.

💰 Dividende

LifeStance Health Group, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

10 analystes évaluent LifeStance Health Group, Inc. (LFST) au consensus : Acheter. L'objectif de cours moyen est de 9,20 €, soit un potentiel de +17.48% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 7,85 € à 11,33 €.

LifeStance Health Group, Inc. : la thèse d'investissement en détail

LifeStance Health Group, Inc. (LFST) operates in the Healthcare — specifically Medical Care Facilities — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 21.2% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Earnings growth of 1927.5% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. Wall Street consensus sits at Buy with an average price target implying roughly 17.48% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

With a net margin of just 1.55%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

The EV/EBITDA multiple of 36.16x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The forward P/E of 22.91x is meaningfully below the trailing 149.67x — analysts expect earnings to step up; the next earnings release is the test.
• The share is trading at 97.7% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to market-like volatility.

Trading Data

Related Stocks in the Same Sector

Where can I buy LifeStance Health Group, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.